DAVID M. SALERNO, M.D., Ph.D.; MORRISON HODGES, M.D.; GREGORY GRANRUD, M.D.; PATRICIA SHARKEY, R.N.
In a randomized placebo-controlled double-blind trial, we compared flecainide to quinidine for treatment of ventricular ectopic depolarizations in 19 patients. The mean percent suppression of total ventricular ectopic depolarizations was 95% for flecainide and 56% for quinidine (p < 0.05). A greater than 80% reduction of total ventricular ectopic depolarizations was obtained in eight of nine patients given flecainide and in five of ten patients given quinidine (p = 0.09). After the randomized protocol, the patients who had received quinidine were given flecainide; 9 of the 10 patients had greater than 80% reduction of total ventricular ectopic depolarizations. Flecainide produced 100% suppression of nonsustained ventricular tachycardia and 99.5% suppression of paired ventricular depolarizations. Flecainide prolonged the PR and QRS intervals; quinidine prolonged the PR and JTC intervals. Side effects were commoner with quinidine than flecainide (p = 0.06). Three other patients failed to complete the protocol because of serious adverse experiences.
SALERNO DM, HODGES M, GRANRUD G, et al. Comparison of Flecainide with Quinidine for Suppression of Chronic Stable Ventricular Ectopic Depolarizations: A Double-Blind Randomized Study in Ambulatory Outpatients. Ann Intern Med. 1983;98:455–460. doi: https://doi.org/10.7326/0003-4819-98-4-455
Download citation file:
Published: Ann Intern Med. 1983;98(4):455-460.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use